This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletr...This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletriptan. Patients (N = 613; female 79%; mean age 39 years) meeting International Headache Society criteria for migraine were encouraged, but not required, to utilize early treatment, thus providing an opportunity to assess the relative contribution to efficacy of pain severity and timing of dose. For the total patient sample (mild-to-severe headaches), 2-h pain-free rates were significantly higher than placebo (22%) on both eletriptan 20 mg (35%; P < 0.01) and eletriptan 40 mg (47%; P < 0.0001). For the cohort of patients who treated their headache when the pain intensity was mild, the 2-h pain-free rate on eletriptan 40 mg was 68%compared with 25%on placebo (P < 0.0001). Pain intensity at the time of taking eletriptan appeared to influence outcome more than the timing of the dose relative to headache onset. Eletriptan was well-tolerated, with adverse event rates similar to placebo when mild headaches were treated.展开更多
Introduction.- Although research suggests that early treatment of migraine h eadache when the pain is mild results in better outcomes for patients, many pati ents delay taking their acute- migraine medication until th...Introduction.- Although research suggests that early treatment of migraine h eadache when the pain is mild results in better outcomes for patients, many pati ents delay taking their acute- migraine medication until their headaches are mo derate or severe. Understanding when and why patients use their migraine medicat ions is an important first step to improve migraine management. Methods.- A pro spective observational study, conducted at a major national retail pharmacy chai n with stores across the United States between April 2001 and November 2002, enr olled men and women between 18 and 55 years of age with a physician diagnosis of migraine with or without aura. Baseline data on 690 pa tients included patient demographics, migraine history, medication use, tendency to avoid or delay treatment of a migraine attack, and reasons for delaying trea tment. Reasons for delaying treatment were assessed via a checklist of nine pote ntial reasons. In the follow- up survey completed after treatment of the next m igraine attack, patients reported the timing of medication use in relation to pa in onset and the severity of the migraine headache at the time they took the med ication. Results.- Despite the severity of their typical migraine attacks, appr oximately 49% of the respondents answered, “ yes” to the question, “ Do yo u often avoid or delay taking your migraine medications when you start to experi ence a migraine attack?” The two most common rationales for avoiding or delayi ng treatment were “ wanting to wait and see if it is really a migraine attack” (69% ) followed by “ only want to take medications if it is a severe attack ” (46% ). In the follow- up survey, regardless of medication used, about 85 % of patients did not treat their next migraine attack until the headache pain was moderate or severe, although 74% treated within 1 hour of pain onset. Con clusion.- These results suggest that patients with migraine often delay their t reatment until they have identified their attack as a migraine. In a展开更多
文摘This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletriptan. Patients (N = 613; female 79%; mean age 39 years) meeting International Headache Society criteria for migraine were encouraged, but not required, to utilize early treatment, thus providing an opportunity to assess the relative contribution to efficacy of pain severity and timing of dose. For the total patient sample (mild-to-severe headaches), 2-h pain-free rates were significantly higher than placebo (22%) on both eletriptan 20 mg (35%; P < 0.01) and eletriptan 40 mg (47%; P < 0.0001). For the cohort of patients who treated their headache when the pain intensity was mild, the 2-h pain-free rate on eletriptan 40 mg was 68%compared with 25%on placebo (P < 0.0001). Pain intensity at the time of taking eletriptan appeared to influence outcome more than the timing of the dose relative to headache onset. Eletriptan was well-tolerated, with adverse event rates similar to placebo when mild headaches were treated.
文摘Introduction.- Although research suggests that early treatment of migraine h eadache when the pain is mild results in better outcomes for patients, many pati ents delay taking their acute- migraine medication until their headaches are mo derate or severe. Understanding when and why patients use their migraine medicat ions is an important first step to improve migraine management. Methods.- A pro spective observational study, conducted at a major national retail pharmacy chai n with stores across the United States between April 2001 and November 2002, enr olled men and women between 18 and 55 years of age with a physician diagnosis of migraine with or without aura. Baseline data on 690 pa tients included patient demographics, migraine history, medication use, tendency to avoid or delay treatment of a migraine attack, and reasons for delaying trea tment. Reasons for delaying treatment were assessed via a checklist of nine pote ntial reasons. In the follow- up survey completed after treatment of the next m igraine attack, patients reported the timing of medication use in relation to pa in onset and the severity of the migraine headache at the time they took the med ication. Results.- Despite the severity of their typical migraine attacks, appr oximately 49% of the respondents answered, “ yes” to the question, “ Do yo u often avoid or delay taking your migraine medications when you start to experi ence a migraine attack?” The two most common rationales for avoiding or delayi ng treatment were “ wanting to wait and see if it is really a migraine attack” (69% ) followed by “ only want to take medications if it is a severe attack ” (46% ). In the follow- up survey, regardless of medication used, about 85 % of patients did not treat their next migraine attack until the headache pain was moderate or severe, although 74% treated within 1 hour of pain onset. Con clusion.- These results suggest that patients with migraine often delay their t reatment until they have identified their attack as a migraine. In a
